Monosomic Loss of MiR15a/MiR16-1 is a Driver of Multiple Myeloma Proliferation and Disease Progression

Marta Chesi, Caleb K. Stein, Victoria M. Garbitt, Meaghen E. Sharik, Yan W. Asmann, Matteo Bergsagel, Daniel L. Riggs, Seth J. Welsh, Erin W. Meermeier, Shaji K. Kumar, Esteban Braggio, P. Leif Bergsagel

Research output: Contribution to journalArticlepeer-review


The most common genetic abnormality in multiple myeloma is the deletion of chromosome 13, seen in almost half of newly diagnosed patients. Unlike chronic lymphocytic leukemia, where a recurrent minimally deleted region including MIR15A/MIR16-1 has been mapped, the deletions in multiple myeloma predominantly involve the entire chromosome and no specific driver gene has been identified. Additional candidate loci include RB1 and DIS3, but while biallelic deletion of RB1 is associated with disease progression, DIS3 is a common essential gene and complete inactivation is not observed. The Vk*MYC transgenic mouse model of multiple myeloma spontaneously acquires del(14), syntenic to human chromosome 13, and Rb1 complete inactivation, but not Dis3 mutations. Taking advantage of this model, we explored the role in multiple myeloma initiation and progression of two candidate loci on chromosome 13: RB1 and MIR15A/MIR16-1. Monoallelic deletion of Mir15a/Mir16-1, but not Rb1, was sufficient to accelerate the development of monoclonal gammopathy in wildtype mice and the progression of multiple myeloma in Vk*MYC mice, resulting in increased expression of Mir15a/Mir16-1 target genes and plasma cell proliferation, which was similarly observed in patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)68-81
Number of pages14
JournalBlood cancer discovery
Issue number1
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Monosomic Loss of MiR15a/MiR16-1 is a Driver of Multiple Myeloma Proliferation and Disease Progression'. Together they form a unique fingerprint.

Cite this